Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study

Shao Z.Tseng L.-M.CHIUN-SHENG HUANGPang D.Yang Y.Li W.Liao N.Geng C.Zhang Q.Xu B.Liu D.Kwong A.et al (continued in the appendix)2021-04-262021-04-2620211465-3621https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102607614&doi=10.1093%2fjjco%2fhyaa216&partnerID=40&md5=004cc33a2d135f780c71dfc450691891https://scholars.lib.ntu.edu.tw/handle/123456789/557876Background: The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational ranadjuvant; breast cancer; Chinese; HER2; pertuzumab[SDGs]SDG3pertuzumab; placebo; trastuzumab; antineoplastic agent; epidermal growth factor receptor 2; monoclonal antibody; pertuzumab; trastuzumab; adjuvant chemotherapy; adult; aged; Article; China; Chinese; clinical outcome; clinical trial; demography; diarrhea;Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY studyjournal article10.1093/jjco/hyaa216336195502-s2.0-85102607614